If you have been reading about Angiotensin IV analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
== 19th century: the emergence of biological disciplines == Up through the 19th century, the scope of biology was largely divided between medicine, which investigated questions of form and function (i.e., physiology), and natural history, which was concerned with the diversity of life and interactions among different forms of life and between life and non-life. By 1900, much of these domains overlapped, while natural history (and its counterpart natural philosophy) had largely given way to more specialized scientific disciplines—cytology, bacteriology, morphology, embryology, geography, and geology.
The androgen backdoor pathways are vital for creating androgens from 21-carbon (C21) steroids, known as pregnanes. A 21-carbon steroid is a steroid molecule with 21 carbon atoms, hence, their chemical formula contains C21. For example, the chemical formula of progesterone is C21H30O2. For this reason, 21-carbon steroids are denoted as C21-steroids, 19-carbon steroids are denoted as C19 steroids, and so on. The androgen backdoor pathways occur without the involvement of testosterone (T) and/or androstenedione (A4), which are part of the conventional, canonical (classic) androgenic pathway. In the canonical pathways of androgen biosynthesis, DHT is synthesized from T via 5α-reduction, so that 5α-reduction of T, a C19 steroid, is the last step of the pathway (see Dihydrotestosterone § Biosynthesis). In the backdoor pathways, to the contrary, 5α-reduction of C21 steroids is the first step. The 5α-reduction is a chemical reaction where a functional group attached to the carbon in position 5α of the steroid nucleus is reduced, and a double bond between carbon atoms numbered 4 and 5 in the steroid molecule is replaced to the single bond in a chemical reaction catalyzed by the SRD5A1 enzyme. The androgen backdoor pathways can be also activated in pathologic conditions (diseases), such as congenital adrenal hyperplasia (CAH), leading to hyperandrogenism.
=== Cancer === After finding that Ras proteins are mutated in 30% of human cancers, it was suspected that mutated Rho proteins might also be involved in cancer reproduction. However, as of August 2007, no oncogenic mutations have been found in Rho proteins, and only one has been found to be genetically altered. To explain the role of Rho pathways without mutation, researchers have now turned to the regulators of rho activity and the levels of expression of the Rho proteins for answers. One way to explain altered signaling in the absence of mutation is through increased expression. Overexpression of RhoA, RhoB, RhoC, Rac1, Rac2, Rac3, RhoE, RhoG, RhoH, and Cdc42 has been shown in multiple types of cancer. This increased presence of so many signaling molecules implies that these proteins promote the cellular functions that become overly active in cancerous cells. A second target to explain the role of the Rho proteins in cancer is their regulatory proteins. Rho proteins are very tightly controlled by a wide variety of sources, and over 60 activators and 70 inactivators have been identified. Multiple GAPs, GDIs, and GEFs have been shown to undergo overexpression, downregulation, or mutation in different types of cancer. Once an upstream signal is changed, the activity of its targets downstream—i.e., the Rho proteins—will change in activity. Ellenbroek et al. outlined a number of different effects of Rho activation in cancerous cells. First, in the initiation of the tumor modification of Rho activity can suppress apoptosis and therefore contribute to artificial cell longevity.
=== Reported end of outbreak: August–September 2022 === On 5 August 2022, the country reported that it had not seen a fever case for seven consecutive days, and that every fever case had recovered. On 8 August, plans were announced to convene the Supreme People's Assembly in September, moving its members out of isolation. A separate review meeting to discuss a "change in direction" in pandemic response was also announced. On 11 August, Kim Jong Un's sister, Kim Yo Jong, stated that her brother had had a fever, implying that he had COVID-19 at one point. She also blamed South Korea for the COVID-19 outbreak in the country, claiming that it sent contaminated anti-Pyongyang leaflets to spread the disease. North Korean media reports indicate that the population have resumed regular activity. On August 25, several sources told NK News that North Korea could possibly allow foreigners into North Korea for the first time since 2020, likely after the 20th National Congress of the Chinese Communist Party later in 2022. In September, however, Kim Jong Un flagged the first rollout of vaccines in November and warned that COVID-19 could reappear in the winter months. The mass vaccination program started in the border areas in late September, making North Korea the last country in the world other than Eritrea to have a mass vaccination program against COVID-19.
Sources: en.wikipedia.org
=== Horizontal plate filters === Horizontal plate filter paper is commonly utilized in industrial processing. Filter paper typically is designed to fit the manufacturers specifications. Absolute micron retention can range from 1–100 microns but Diatomaceous earth is commonly used with filter paper to obtain sub-micron filtration. Activated carbon or other filter aids can be used with the filter paper to form a filter cake to achieve specific results. Filter paper can be impregnated with DE or activated carbon.
== History == In 1950, Jack Gross, a Canadian endocrinologist, came to the British National Institute for Medical Research to work with Rosalind Pitt-Rivers as a postdoctoral fellow. Gross had previous experience working at McGill University under Professor Charles Leblond, where they used radioactive iodine to study the physiology of thyroid hormone and applied chromatography to analyze radioiodinated proteins in human blood after radioiodine therapy. Gross and Leblond found an unknown radioactive compound in the blood of rats given radioactive iodine. The compound migrated close to thyroxine in chromatography and they initially named it 'unknown 1'. Around that time a group led by Jean Roche in Paris described a deiodinating activity in the sheep thyroid gland, raising the possibility that 'unknown 1' is the less iodinated analogue of T4, triiodothyronine. In March of 1952, Gross and Pitt-Rivers published a paper in The Lancet titled "The identification of 3: 5: 3'-L-triiodothyronine in human plasma". While Gross & Pitt-Rivers are normally credited with discovering T3, this compound was actually first isolated by the biochemists Hird and Trikojus at the University of Melbourne in 1948. It has been suggested that their published paper was little-known and therefore easily ignored. It has also been stated that Pitt-Rivers had read this paper but failed to mention it. Between 2020 and 2024, in numerous studies, an association was observed between serum free triiodothyronine (fT3) concentrations and the prognosis of severe COVID-19 in patients with SARS-CoV-2 infection.
As another example, the ratio of dextromethorphan (a drug that is mainly metabolized by CYP2D6) to its major metabolite dextrorphan increased approximately 35-fold when it was administered to people being treated with 300 mg/day bupropion. When people on bupropion are given MDMA, about 30% increase of exposure to both drugs is observed, with enhanced mood but decreased heart rate effects of MDMA. Interactions with other CYP2D6 substrates, such as metoprolol, imipramine, nortriptyline, venlafaxine, and nebivolol have also been reported. However, in a notable exception, bupropion does not seem to affect the concentrations of CYP2D6 substrates fluoxetine and paroxetine. Bupropion prevents norepinephrine and dopamine release induced by methamphetamine and has been found to reduce the subjective and sympathomimetic effects of methamphetamine in humans. Bupropion lowers the seizure threshold, and therefore can potentially interact with other medications that also lower it, such as antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids. The prescribing information recommends minimizing the use of alcohol, since in rare cases bupropion reduces alcohol tolerance. Caution should be observed when combining bupropion with a monoamine oxidase inhibitor (MAOI), as it may result in hypertensive crisis.
In 2011, CLASP was appointed as the Operating Agent for the Super-efficient Equipment and Appliance Deployment (SEAD) initiative, a multilateral collaboration initiated by the Clean Energy Ministerial (CEM) and the International Partnership for Energy Efficiency Cooperation (IPEEC) to transform the global market toward higher energy efficiency. SEAD member governments include Australia, Brazil, Canada, the European Commission, France, Germany, India, Japan, Korea, Mexico, Russia, South Africa, Sweden, the United Arab Emirates, the United Kingdom, and the United States. China participates as an observer.
After collection, sperm must be processed for storage. According to the Sperm Bank of California, sperm banks can use the 'unwashed' or 'wash' method to process sperm samples. The 'wash' method includes removing unwanted particles and adding buffer solutions to preserve viable sperm. However, this approach can contribute to further stress on the sperm cells and decrease the survival of sperm after freezing. The 'unwashed' approach allows for more flexibility to freeze the semen sample, and increases the number of sperm that survive. A cryoprotectant semen extender is conducted if the semen sample is placed in a freezer for storage. Semen extenders play a key role in protecting sperm from 'freeze and osmotic shock, oxidative stress, and cell injury' due to the formation of ice crystals during frozen storage. The semen is preserved by stabilizing the properties of the sperm cells such as the membrane, motility, and 'DNA integrity' in order to create a sustainable viable environment. There are two common forms of medium for sperm cyropreservation, one containing egg yolk from hens and glycerol, and the other containing just glycerol. One study in 2009 compared media supplemented with egg yolk and media supplemented with soy lecithin, finding that there was no significance between sperm motility, morphology, chromatin decondensation, or binding between the two, indicating that soy lecithin may be a viable alternative to egg yolk.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.